Toronto Dominion Bank’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.84M Buy
50,000
+20,000
+67% +$948K ﹤0.01% 1175
2025
Q4
$1.53M Sell
30,000
-28,300
-49% -$1.45M ﹤0.01% 1176
2025
Q3
$3.24M Buy
58,300
+28,300
+94% +$1.66M 0.01% 912
2025
Q2
$2.07M Hold
30,000
﹤0.01% 972
2025
Q1
$2.08M Sell
30,000
-7,400
-20% -$611K ﹤0.01% 927
2024
Q4
$3.22M Buy
+37,400
New +$4.04M 0.01% 812

Other funds holding NVO

Toronto Dominion Bank's NVO Position: Q1 2026 in Review

Toronto Dominion Bank reduced its Novo Nordisk (NVO) stake by 99% in Q1 2026, selling an estimated $756K and leaving 86 shares worth $3.15K. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

Toronto Dominion Bank first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.96M in Q2 2024. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Toronto Dominion Bank held 86 shares of Novo Nordisk worth $3.15K as of Q1 2026.
  • Toronto Dominion Bank sold 15,962 Novo Nordisk shares in Q1 2026, an estimated $756K.
  • Novo Nordisk made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #1991 holding.
  • Toronto Dominion Bank first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Toronto Dominion Bank's Novo Nordisk position peaked at $4.96M in Q2 2024.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.